Gasporox: Catching its breath after a strong H1 2023

Research Update

2023-11-08

07:35

Redeye provides an update on Gasporox after its Q3 2023 report. The report came in weaker-than-expected after H1 2023 results exceeding our expectations significantly. While we are pleased by AutoMap already receiving orders worth SEK3m, we have less optimistic Gasporox will manage to grow in H1 2024 due to the strong 2023 results. Thus, we reduce our fair value range while we remain optimistic about the long-term.

Rasmus Jacobsson

Martin Wahlström

Contents

Due diligence on CCIT market and the EU Annex 1

Download article

Below expectations while still EBITDA positive

Net Sales came in at SEK6.8m, 4% y/y, well below our estimated SEK8.8m (deviation -23%). Sales were broad-based, with sensors and instruments contributing to the results. EBITDA came in at SEK0.5m, corresponding to an EBITDA margin of 7% (EBITDA SEK1.1m, EBITDA-margin 17% last year). Thus, it is well below our estimate of SEK2.2m.

Order for AutoMap secured

During the quarter, Gasporox received two larger orders (press released as they are >10% of the previous year’s sales). The first one is from MaxCann worth SEK4m, which will be delivered in H2 2023 and H1 2024 and is for the VialArch, launched in autumn 2021. Gasporox’s recently launched AutoMap also received an order from Weber worth SEK3m, set to be delivered in 2023 and 2024. AutoMap was launched in May 2023. EU Annex 1 has recently been revised, resulting in more stringent CCIT requirements. We believe the AutoMap product is well-positioned to capitalize on the revised EU Annex 1. The total press released “order book” stands at SEK7m, set to be delivered in 2023 and 2024.

Revised fair value range

We are increasingly convinced Gasporox will struggle to show growth for H1 2024 due to the strong H1 2023. Additionally, we reduce our Q4 2023 estimate. Hence, we have lowered our Q4 2023 net sales estimate by 24% and our 2024 estimate by 21%. Due to operating leverage, our EBITDA estimates are reduced by 81% and 26% for Q4 2023 and 2024, respectively. We have increased our risk-free rate assumption from 2.5% to 3.0% due to higher interest rates. We remain confident that Gasporox can reach cash flow positive on its current funding. Due mainly to estimate changes, we reduce our fair value range from SEK12.0-45.0 with a base case of SEK25.0 to SEK9.0-36.0 with a base case of SEK21.0.

Key financials

SEKm202120222023e2024e2025e
Revenues15.721.431.134.947.1
Revenue Growth26.4%36.3%44.9%12.3%35.0%
EBITDA-2.7-0.905.27.110.0
EBIT-5.4-4.20.941.73.9
EBIT Margin-34.2%-19.7%3.0%4.9%8.2%
Net Income-5.4-4.40.200.923.1
EV/Revenue5.63.83.53.22.3
EV/EBIT-16.3-19.211664.828.3

Due diligence on CCIT market and the EU Annex 1

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.

Contents

Due diligence on CCIT market and the EU Annex 1

Download article